Study Results. For purposes of clarity (a) the Parties hereby acknowledge and agree, in accordance with Section 1.77, that (1) all data and information obtained or produced in the conduct of the Feasibility Study and/or the Target Confirmation Study (the “Study Results”) shall be jointly owned by the Parties and (2) subject to subsection (b) below, neither Party shall cause or allow any Study Results to be published without the prior written consent of the other Party; and (b) notwithstanding anything to the contrary in Section 10.4, Section 1.77 or subsection (D)(a) above, on and after the date on which [***] becomes a Waived Target pursuant to this Agreement, (1) DICERNA shall solely own the Study Results and have the sole right to use such Study Results for any and all purposes, inside or outside of this Agreement, without restriction, (2) DICERNA shall be deemed to have granted KHK the right to use such Study Results solely for internal research purposes and (3) as between the Parties, DICERNA shall have the sole right to publish such Study Results; provided, that, (i) any contribution of KHK to the Study Results shall be duly recognized and co-authorship shall be determined in accordance with customary industry standards and (ii) to the extent that any such Study Results to be published contain any Confidential Information of KHK, including without limitation KHK [***] DDS Technology or KHK Program Technology, DICERNA shall obtain the prior written consent of KHK to such publication.
Appears in 3 contracts
Sources: Research Collaboration and License Agreement (Dicerna Pharmaceuticals Inc), Research Collaboration and License Agreement (Dicerna Pharmaceuticals Inc), Research Collaboration and License Agreement (Dicerna Pharmaceuticals Inc)